Latest News

Head-To-Head Contrast: Genmab A/S (GMAB) versus Its Rivals

Genmab A/S (NASDAQ: GMAB) is one of 593 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Genmab A/S to similar businesses based on the strength of its earnings, analyst recommendations, institutional ownership, valuation, risk, dividends and profitability.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Institutional and Insider Ownership

7.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 45.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.9% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genmab A/S 42.39% 16.26% 15.23%
Genmab A/S Competitors -2,515.70% -859.49% -32.09%

Analyst Ratings

This is a summary of current ratings for Genmab A/S and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S 0 0 6 0 3.00
Genmab A/S Competitors 5774 15711 31386 1200 2.52

Genmab A/S presently has a consensus price target of $23.67, suggesting a potential downside of 1.47%. As a group, “Pharmaceutical preparations” companies have a potential upside of 50.47%. Given Genmab A/S’s competitors higher possible upside, analysts plainly believe Genmab A/S has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Genmab A/S and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Genmab A/S $479.18 million $233.19 million 6.39
Genmab A/S Competitors $2.11 billion $223.97 million -3.58

Genmab A/S’s competitors have higher revenue, but lower earnings than Genmab A/S. Genmab A/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Genmab A/S beats its competitors on 7 of the 12 factors compared.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Leave a Reply

Your email address will not be published. Required fields are marked *